Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 11,904 Shares

Key Points

• Director sale: Dyne director Jason Rhodes sold 11,904 shares on May 4 at an average price of $18 under a pre-arranged Rule 10b5-1 plan, cutting his holdings by 58.48% to 8,450 shares (SEC Form 4 disclosure).
• Stock move & valuation: Shares rose 7.8% to $18.84; the company has a market cap of $3.11B, a negative trailing P/E (-5.32), a 52‑week range of $8.06–$25.00, and a consensus analyst rating of "Moderate Buy" with an average price target of $35.14.
• Institutional ownership: Institutions own 96.68% of the stock, with notable activity including Goldman Sachs increasing its stake by 58.2% (adding 366,183 shares) and several firms initiating or expanding positions.

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) Director Jason Rhodes sold 11,904 shares of the business's stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $18.00, for a total transaction of $214,272.00. Following the completion of the sale, the director directly owned 8,450 shares in the company, valued at $152,100. This trade represents a 58.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Trading Up 7.8%

Shares of Dyne Therapeutics stock traded up $1.37 on Wednesday, reaching $18.84. The company had a trading volume of 1,720,199 shares, compared to its average volume of 2,090,953. The firm's 50 day moving average price is $17.94 and its two-hundred day moving average price is $18.56. The firm has a market cap of $3.11 billion, a PE ratio of -5.32 and a beta of 1.08. Dyne Therapeutics, Inc. has a 52-week low of $8.06 and a 52-week high of $25.00. The company has a debt-to-equity ratio of 0.15, a quick ratio of 22.25 and a current ratio of 22.25.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings data on Monday, March 2nd. The company reported ($0.76) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.02). Sell-side analysts predict that Dyne Therapeutics, Inc. will post -2.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in DYN. AQR Capital Management LLC acquired a new position in Dyne Therapeutics during the 1st quarter worth approximately $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Dyne Therapeutics by 5.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company's stock worth $597,000 after acquiring an additional 2,886 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Dyne Therapeutics by 58.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company's stock worth $10,407,000 after acquiring an additional 366,183 shares in the last quarter. Caxton Associates LLP acquired a new position in Dyne Therapeutics during the 1st quarter worth approximately $157,000. Finally, Creative Planning grew its holdings in Dyne Therapeutics by 23.8% during the 2nd quarter. Creative Planning now owns 14,541 shares of the company's stock worth $138,000 after acquiring an additional 2,797 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on DYN shares. JPMorgan Chase & Co. dropped their price objective on shares of Dyne Therapeutics from $17.00 to $16.00 and set a "neutral" rating for the company in a report on Tuesday, January 20th. Chardan Capital restated a "buy" rating and issued a $38.00 price objective on shares of Dyne Therapeutics in a report on Monday, March 9th. Weiss Ratings restated a "sell (d-)" rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Morgan Stanley dropped their price objective on shares of Dyne Therapeutics from $50.00 to $47.00 and set an "overweight" rating for the company in a report on Monday, March 2nd. Finally, Jefferies Financial Group restated a "buy" rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Three analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $35.14.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.